MA39485A - Méthode de traitement de la dépression et du trouble dépressif majeur - Google Patents

Méthode de traitement de la dépression et du trouble dépressif majeur

Info

Publication number
MA39485A
MA39485A MA039485A MA39485A MA39485A MA 39485 A MA39485 A MA 39485A MA 039485 A MA039485 A MA 039485A MA 39485 A MA39485 A MA 39485A MA 39485 A MA39485 A MA 39485A
Authority
MA
Morocco
Prior art keywords
depressive disorder
major depressive
treating depression
depression
treating
Prior art date
Application number
MA039485A
Other languages
English (en)
Inventor
Jarlath Ffrench-Mullen
Eric Lai
Original Assignee
Takeda Pharmaceuticals Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Pharmaceuticals Co filed Critical Takeda Pharmaceuticals Co
Publication of MA39485A publication Critical patent/MA39485A/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/112—Disease subtyping, staging or classification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/16—Primer sets for multiplex assays

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Pathology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MA039485A 2014-03-05 2015-03-04 Méthode de traitement de la dépression et du trouble dépressif majeur MA39485A (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201461948529P 2014-03-05 2014-03-05
US201462061417P 2014-10-08 2014-10-08

Publications (1)

Publication Number Publication Date
MA39485A true MA39485A (fr) 2015-09-11

Family

ID=54055831

Family Applications (1)

Application Number Title Priority Date Filing Date
MA039485A MA39485A (fr) 2014-03-05 2015-03-04 Méthode de traitement de la dépression et du trouble dépressif majeur

Country Status (12)

Country Link
US (1) US20170137880A1 (fr)
EP (1) EP3114239A4 (fr)
JP (1) JP2017512204A (fr)
KR (1) KR20160127126A (fr)
CN (1) CN106536751A (fr)
AU (1) AU2015227296A1 (fr)
CA (1) CA2940683A1 (fr)
IL (1) IL247379A0 (fr)
MA (1) MA39485A (fr)
MX (1) MX2016011384A (fr)
RU (1) RU2016138574A (fr)
WO (1) WO2015134585A1 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017087735A1 (fr) * 2015-11-18 2017-05-26 Millennium Pharmaceuticals, Inc. Procédé de traitement de la maladie de crohn

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2044043B2 (fr) * 2006-06-16 2021-03-03 H. Lundbeck A/S 1-[2-(2, 4-dimethylphenylsulfanyl)-phenyl]piperazine hydrobromide comme compose presentant une activite sur la serotonine, 5-ht3 et 5-ht1a pour le traitement du deficit cognitif
EP2581458A3 (fr) * 2008-01-17 2013-07-17 Suregene LLC Marqueurs génétiques de maladie mentale
WO2012031008A2 (fr) * 2010-08-31 2012-03-08 The General Hospital Corporation Matières biologiques liées au cancer dans des microvésicules
WO2012041332A2 (fr) * 2010-10-01 2012-04-05 Rigshospitalet Variations génétiques du gène du récepteur d'interleukine-6 permettant de prédire la réponse de patients au traitement basé sur des inhibiteurs dudit récepteur d'interleukine-6
US9243464B2 (en) * 2011-02-10 2016-01-26 Baker Hughes Incorporated Flow control device and methods for using same
WO2012109565A1 (fr) * 2011-02-10 2012-08-16 Neurotherics, Llc Identification génétique de réponse à des médicaments antidépresseurs
IN2014DN04226A (fr) * 2011-11-14 2015-05-22 Gen Hospital Corp

Also Published As

Publication number Publication date
RU2016138574A (ru) 2018-04-06
IL247379A0 (en) 2016-11-30
RU2016138574A3 (fr) 2018-10-12
CA2940683A1 (fr) 2015-09-11
MX2016011384A (es) 2017-05-01
US20170137880A1 (en) 2017-05-18
EP3114239A4 (fr) 2017-10-11
JP2017512204A (ja) 2017-05-18
KR20160127126A (ko) 2016-11-02
EP3114239A1 (fr) 2017-01-11
WO2015134585A1 (fr) 2015-09-11
AU2015227296A1 (en) 2016-09-08
CN106536751A (zh) 2017-03-22

Similar Documents

Publication Publication Date Title
MA47095A (fr) Traitement du palais mou
IL290985A (en) Methods for diagnosing and treating anxiety disorder
BR112016023105A2 (pt) escalonamento de processos e métodos
DK3233071T3 (da) Fremgangsmåde til behandling eller forebyggelse af Ras-medierede sygdomme
BR112016023582A2 (pt) método de tratamento de um material
BR112016025413A2 (pt) método de fabricação de um inserto e inserto
KR20180084834A (ko) 장치 및 그러한 장치의 제조 방법
MA41462A (fr) Méthode de traitement de maladies
KR20180084734A (ko) 환원수의 제조 장치 및 환원수의 제조 방법
MA41636A (fr) Méthode de traitement de la cholangite sclérosante primitive
MA42444A (fr) Traitement du prurit
MA39485A (fr) Méthode de traitement de la dépression et du trouble dépressif majeur
NO20150468A1 (no) Peleskjøt og fremgangsmåte for bruk
BR112016028653A2 (pt) métodos de tratamento de doenças e distúrbios neurodesenvolvimentais
GB2542741B (en) Soundboard apparatus and method of forming
DE102014014705A8 (de) Ophthalmologisches System und Verfahren zum Betreiben eines solchen
FI20160064A (fi) Menetelmä seulomiseen ja seulontalaite
FR3044440B1 (fr) Methode de modelisation de contraintes
FR3025406B1 (fr) Echantillon cosmetique emballe et procede de fabrication
FI20145670A (fi) Menetelmä ja järjestelmä sisältöjulkaisun tuottamiseksi
MA49378A (fr) Méthode de traitement de la thrombocytopénie immunitaire
TH1501004555A (th) อุปกรณ์สำหรับการดำเนินกรรมวิธีชิ้นส่วนของพืชและวิธีการของอุปกรณ์
FI20145163A (fi) Järjestely ja menetelmä prosessin simuloimiseksi
TH1601003559A (th) วิธีการในการผลิต 2-ฟลูออโร-4-โบรอโน-l-เฟนิลอะลานีนและสารตั้งต้นของ 2-ฟลูออโร-4-โบรอโน-l-เฟนิลอะลานีน
FR3017372B1 (fr) Caisse montable et demontable et procede de montage